Citation

Caselli RJ, Yaari R. J. Trauma. Stress 2008; 22(6): 489-498.

Affiliation

Department of Neurology, Mayo Clinic and Arizona Alzheimer's Disease Consortium, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu

Copyright

(Copyright © 2008, International Society for Traumatic Stress Studies, Publisher John Wiley and Sons)

DOI

10.1177/1533317507306654

PMID

18166608

Abstract

There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

Language: en